MiNK Therapeutics, Inc. (INKT): Price and Financial Metrics
INKT Price/Volume Stats
| Current price | $0.52 | 52-week high | $1.90 |
| Prev. close | $0.50 | 52-week low | $0.46 |
| Day low | $0.48 | Volume | 101,400 |
| Day high | $0.53 | Avg. volume | 85,920 |
| 50-day MA | $0.69 | Dividend yield | N/A |
| 200-day MA | $0.85 | Market Cap | 20.72M |
INKT Stock Price Chart Interactive Chart >
MiNK Therapeutics, Inc. (INKT) Company Bio
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate includes AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.
INKT Price Returns
| 1-mo | -24.65% |
| 3-mo | -31.02% |
| 6-mo | -42.22% |
| 1-year | -48.51% |
| 3-year | -87.38% |
| 5-year | N/A |
| YTD | -51.40% |
| 2023 | -59.00% |
| 2022 | -41.48% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...